The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: Mechanisms of action

Drug Discovery Today

Volumn 21, Issue 5, 2016, Pages 802-818

  Athauda, Dilan ^a   Foltynie, Thomas ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; GLUCAGON LIKE PEPTIDE 1; PROTEIN KINASE B;

ALZHEIMER DISEASE; DISEASE SEVERITY; EXPERIMENTAL MODEL; HUMAN; INSULIN RESISTANCE; LEARNING; MEMORY; MITOCHONDRION; MOLECULAR MECHANICS; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INSULIN RESISTANCE; LEARNING; MITOCHONDRIA; NEUROGENESIS; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84957388554     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.01.013     Document Type: Review

References (255)

1. D.J. Irwin, and et al. Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies Nat. Rev. Neurosci. 14 2013 626 636
2. J.A. Lovshin, and D.J. Drucker Incretin-based therapies for type 2 diabetes mellitus Nat. Rev. Endocrinol. 5 2009 262 269
3. D.J. Drucker, and et al. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits Diabetes Care 33 2010 428 433
4. K.M. Heppner, and et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain Endocrinology 156 2015 255 267
5. E. Alvarez, and et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem J. Neurochem. 92 2005 798 806
6. S.C. Cork, and et al. Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain Mol. Metab. 4 2015 718 731
7. J.F. Habener, and V. Stanojevic Alpha cells come of age Trends Endocrinol. Metab. 24 2013 153 163
8. C. Kappe, and et al. GLP-1 secretion by microglial cells and decreased CNS expression in obesity J. Neuroinflammation 9 2012 276
9. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157
10. T.J. Kieffer, and et al. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585 3596
11. D.J. Drucker Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes Expert Opin. Investig. Drugs 12 2003 87 100
12. J.J. Holst, and et al. Neuroprotective properties of GLP-1: theoretical and practical applications Curr. Med. Res. Opin. 27 2011 547 558
13. D.G. Parkes, and et al. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1 Expert Opin. Drug Discov. 8 2013 219 244
14. R. Gentilella, and et al. Exenatide: a review from pharmacology to clinical practice Diabetes Obes. Metab. 11 2009 544 556
15. A.J. Kastin, and V. Akerstrom Entry of exendin-4 into brain is rapid but may be limited at high doses Int. J. Obes. Relat. Metab. Disord. 27 2003 313 318
16. K. Hunter, and C. Hölscher Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis BMC Neurosci. 13 2012 33
17. A. Harkavyi, and et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease J. Neuroinflammation 5 2008 19
18. Y. Li, and et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism Proc. Natl. Acad. Sci. U. S. A. 106 2009 1285 1290
19. G. Bertilsson, and et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease J. Neurosci. Res. 86 2008 326 338
20. S. Kim, and et al. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease J. Endocrinol. 202 2009 431 439
21. N. Rampersaud, and et al. Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions Neuropeptides 46 2012 183 193
22. W. Liu, and et al. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease Neuroscience 303 2015 42 50
23. N.N. Nassar, and et al. Saxagliptin: a novel antiparkinsonian approach Neuropharmacology 89 2015 308 317
24. 2 Online 10 2012 abst185P
25. S.F.J. McGovern, and et al. Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain Brain Res. 1473 2012 204 213
26. S. Gengler, and et al. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice Neurobiol. Aging 33 2012 265 276
27. X.H. Wang, and et al. Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats Neuroscience 170 2010 1239 1248
28. W-N. Han, and et al. Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats Neurobiol. Aging 34 2013 576 588
29. P.L. McClean, and et al. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease Eur. J. Pharmacol. 630 2010 158 162
30. T. Perry, and et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron J. Neurosci. Res. 72 2003 603 612
31. Y. Li, and et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease J. Alzheimers Dis. 19 2010 1205 1219
32. D.W. Porter, and et al. Four weeks administration of liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance Diabetes Obes. Metab. 12 2010 891 899
33. A. Hamilton, and et al. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain J. Neurosci. Res. 89 2011 481 489
34. J. Kosaraju, and et al. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease Neuropharmacology 72 2013 291 300
35. M. D'Amico, and et al. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice Exp. Gerontol. 45 2010 202 207
36. D-H. Kim, and et al. Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures Neurobiol. Dis. 46 2012 52 58
37. K. Rees, and et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies Cochrane Database Syst. Rev. 11 2011 CD008454
38. 11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat. Disord. 16 2010 57 59
39. Z. Fan, and et al. Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia Alzheimers Dement. 11 2015 608 621
40. M.C. Leal, and et al. Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease? Front. Cell. Neurosci. 7 2013 53
41. K. Imamura, and et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains Acta Neuropathol. 106 2003 518 526
42. T.S. Dixit, and et al. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis Physiol. Behav. 114-115 2013 38 41
43. I. Komsuoglu Celikyurt, and et al. Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes Med. Sci. Monit. Basic Res. 20 2014 112 117
44. A.N. Sharma, and et al. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats Metab. Brain Dis. 30 2015 519 527
45. N. Pessoa Rocha, and et al. Depression and cognitive impairment in Parkinson's disease: a role for inflammation and immunomodulation? Neuroimmunomodulation 21 2014 88 94
46. D. Béraud, and et al. Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein J. Neuroimmune Pharmacol. 8 2013 94 117
47. F. Blandini Neural and immune mechanisms in the pathogenesis of Parkinson's disease J. Neuroimmune Pharmacol. 8 2013 189 201
48. S. Gallegos, and et al. Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease Front. Neurosci. 9 2015 59
49. M.S. Moehle, and A.B. West M1 and M2 immune activation in Parkinson's Disease: foe and ally? Neuroscience 27 2014 59 73
50. K. Sekiyama, and et al. Neuroinflammation in Parkinson's disease and related disorders: a lesson from genetically manipulated mouse models of α-synucleinopathies Parkinsons Dis. 2012 2012 271732
51. Y. Ouchi, and et al. Microglial activation and dopamine terminal loss in early Parkinson's disease Ann. Neurol. 57 2005 168 175
52. S. Iannaccone, and et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease Parkinsonism Relat. Disord. 19 2013 47 52
53. J. Schwenkgrub, and et al. Effect of human interleukin-10 on the expression of nitric oxide synthases in the MPTP-based model of Parkinson's disease Pharmacol. Rep. 65 2013 44 49
54. I. Joniec-Maciejak, and et al. The influence of AAV2-mediated gene transfer of human IL-10 on neurodegeneration and immune response in a murine model of Parkinson's disease Pharmacol. Rep. 66 2014 660 669
55. C.H. Lee, and et al. Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia J. Neurosci. Res. 89 2011 1103 1113
56. S. Teramoto, and et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia J. Cereb. Blood Flow Metab. 31 2011 1696 1705
57. S. Briyal, and et al. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats Brain Res. 1427 2012 23 34
58. V. Darsalia, and et al. Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization PLOS ONE 9 2014 e103114
59. V. Darsalia, and et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in type 2 diabetic rats Clin. Sci. (Lond.) 122 2012 473 483
60. K. Eakin, and et al. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats PLOS ONE 8 2013 e82016
61. N.H. Greig, and et al. Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury Alzheimers Dement. 10 2014 S62 S75
62. D. Tweedie, and et al. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice Exp. Neurol. 239 2013 170 182
63. P.L. McClean, and et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease J. Neurosci. 31 2011 6587 6594
64. V. Solmaz, and et al. Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats Eur. J. Pharmacol. 765 2015 482 487
65. T. Ahern, and et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study J. Eur. Acad. Dermatol. Venereol. 27 2013 1440 1443
66. X. Du, and et al. Anti-inflammatory effect of exendin-4 postconditioning during myocardial ischemia and reperfusion Mol. Biol. Rep. 41 2014 3853 3857
67. M. Arakawa, and et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4 Diabetes 59 2010 1030 1037
68. S. Hunot, and et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease Proc. Natl. Acad. Sci. U. S. A. 94 1997 7531 7536
69. A. Ghosh, and et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 104 2007 18754 18759
70. F. Zhang, and et al. Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity J. Pharmacol. Exp. Ther. 333 2010 822 833
71. G. Zhang, and et al. Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH Nature 497 2013 211 216
72. R.M. Abdelsalam, and M.M. Safar Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways J. Neurochem. 133 2015 700 707
73. L. Han, and et al. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways Diabetes Res. Clin. Pract. 97 2012 453 460
74. Y-S. Lee, and et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes Diabetologia 55 2012 2456 2468
75. Y-T. Chen, and et al. Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction J. Transl. Med. 11 2013 270
76. R. Kodera, and et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes Diabetologia 54 2011 965 978
77. A. Oeckinghaus, and et al. Crosstalk in NF-κB signaling pathways Nat. Immunol. 12 2011 695 708
78. S. Khasnavis, and et al. Suppression of nuclear factor-κB activation and inflammation in microglia by physically modified saline J. Biol. Chem. 287 2012 29529 29542
79. V.M. Hubbard, and et al. Selective autophagy in the maintenance of cellular homeostasis in aging organisms Biogerontology 13 2012 21 35
80. A.H.V. Schapira Mitochondria in the aetiology and pathogenesis of Parkinson's disease Lancet Neurol. 7 2008 97 109
81. Y. Chen, and et al. Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease Eur. J. Pharmacol. 768 2015 21 27
82. M.Y. Kang, and et al. Glucagon-like peptide-1 increases mitochondrial biogenesis and function in INS-1 Rat insulinoma cells Endocrinol. Metab. (Seoul, Korea) 30 2015 216 220
83. H. Li, and et al. Neuroprotective effects of exendin-4 in rat model of spinal cord injury via inhibiting mitochondrial apoptotic pathway Int. J. Clin. Exp. Pathol. 8 2015 4837 4843
84. Y. Fan, and et al. Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis Mol. Vis. 20 2014 1557 1568
85. M. DeNicola, and et al. Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium Am. J. Physiol. Endocrinol. Metab. 307 2014 E630 E643
86. H. Sun, and et al. Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice Cell. Mol. Neurobiol. 33 2013 347 357
87. A. Wiederkehr, and C.B. Wollheim Impact of mitochondrial calcium on the coupling of metabolism to insulin secretion in the pancreatic beta-cell Cell Calcium 44 2008 64 76
88. P.E. Morales, and et al. GLP-1 promotes mitochondrial metabolism in vascular smooth muscle cells by enhancing endoplasmic reticulum-mitochondria coupling Biochem. Biophys. Res. Commun. 446 2014 410 416
89. C. Guardia-Laguarta, and et al. α-Synuclein is localized to mitochondria-associated ER membranes J. Neurosci. 34 2014 249 259
90. H. Zhou, and et al. Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro Sci. Rep. 5 2015 12898
91. Y. Zhan, and et al. Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis Med. Sci. Monit. 18 2012 BR286 BR291
92. D. Tews, and et al. Anti-apoptotic action of exendin-4 in INS-1 beta cells: comparative protein pattern analysis of isolated mitochondria Horm. Metab. Res. 41 2009 294 301
93. Z. Li, and et al. Exendin-4 protects mitochondria from reactive oxygen species induced apoptosis in pancreatic Beta cells PLOS ONE 8 2013 e76172
94. B. Zheng, and et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease Sci. Transl. Med. 2 2010 52ra73
95. J. Clark, and et al. Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease BMC Med. Genet. 12 2011 69
96. A.S. Ebrahim, and et al. Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1alpha enhances alpha-synuclein oligomerization and down regulates AKT/GSK3beta signaling pathway in human neuronal cells that inducibly express alpha-synuclein Neurosci. Lett. 473 2010 120 125
97. M. Boutant, and C. Cantó SIRT1 metabolic actions: integrating recent advances from mouse models Mol. Metab. 3 2014 5 18
98. C. Cantó, and J. Auwerx PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure Curr. Opin. Lipidol. 20 2009 98 105
99. F. Xu, and et al. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis Diabetes 63 2014 3637 3646
100. J. Lee, and et al. Exendin-4 attenuates endoplasmic reticulum stress through a SIRT1-dependent mechanism Cell Stress Chaperones 19 2014 649 656
101. R. Lennox, and et al. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice Neuropharmacology 86 2014 22 30
102. A.Z. Herskovits, and L. Guarente SIRT1 in neurodevelopment and brain senescence Neuron 81 2014 471 483
103. P. Kumar, and et al. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms Behav. Pharmacol. 17 2006 485 492
104. M. Lagouge, and et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha Cell 127 2006 1109 1122
105. M. Terrelonge, and et al. CSF β-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease J. Mol. Neurosci. 58 2015 88 92
106. E. Masliah, and et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 98 2001 12245 12250
107. K.A. Jellinger, and et al. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease J. Neural Transm. 109 2002 329 339
108. P.T. Kotzbauer, and et al. Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia Arch. Neurol. 69 2012 1326 1331
109. Y. Compta, and et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 134 2011 1493 1505
110. Z. Qin, and et al. Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42) Neurosci. Lett. 444 2008 217 221
111. H. Li, and et al. Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse hippocampal dentate gyrus Neurosci. Lett. 486 2010 38 42
112. W. Xu, and et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes J. Investig. Med. 63 2015 267 272
113. S. Chen, and et al. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4 Age (Dordr.) 34 2012 1211 1224
114. J. Kosaraju, and et al. Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease J. Pharm. Pharmacol. 65 2013 1773 1784
115. S. Chen, and et al. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation Neuroscience 256 2014 137 146
116. D-L. Ma, and et al. Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation IN DIABETIC db/db mice J. Neurochem. 135 2015 301 308
117. Y. Yang, and et al. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes J. Alzheimers Dis. 37 2013 637 648
118. M. Medina, and J. Avila New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease Expert Opin. Ther. Targets 18 2014 69 77
119. M. Golpich, and et al. Glycogen synthase kinase-3 beta (GSK-3β) signaling: implications for Parkinson's disease Pharmacol. Res. 97 2015 16 26
120. T. Duka, and et al. Alpha-synuclein contributes to GSK-3beta-catalysed Tau phosphorylation in Parkinson's disease models FASEB J. 23 2009 2820 2830
121. Y-H. Yuan, and et al. The molecular mechanism of rotenone-induced α-synuclein aggregation: emphasizing the role of the calcium/GSK3β pathway Toxicol. Lett. 233 2015 163 171
122. G. Donmez, and T.F. Outeiro SIRT1 and SIRT2: emerging targets in neurodegeneration EMBO Mol. Med. 5 2013 344 352
123. G. Donmez, and et al. SIRT1 protects against α-synuclein aggregation by activating molecular chaperones J. Neurosci. 32 2012 124 132
124. 1-42 in cortical neurons CNS Neurol. Disord. Drug Targets 11 2012 1045 1051
125. J. Liu, and et al. Geniposide decreases the level of Aβ1-42 in the hippocampus of streptozotocin-induced diabetic rats Acta Biochim. Biophys. Sin. (Shanghai) 45 2013 787 791
126. W. Liu, and et al. Neuroprotective effects of geniposide on Alzheimer's disease pathology Rev. Neurosci. 26 2015 371 383
127. S.K. Sharma, and et al. Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner Sci. Rep. 5 2015 12531
128. W.Q. Qiu, and M.F. Folstein Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis Neurobiol. Aging 27 2006 190 198
129. K. Vekrellis, and et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme J. Neurosci. 20 2000 1657 1665
130. S. Sudoh, and et al. Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells Biochemistry 41 2002 1091 1099
131. N. Ohtake, and et al. Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex Regul. Pept. 190-191 2014 1 11
132. C. Zhao, and et al. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus J. Neurosci. 26 2006 3 11
133. G.U. Höglinger, and et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease Nat. Neurosci. 7 2004 726 735
134. G.C. O'Keeffe, and et al. Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF Proc. Natl. Acad. Sci. U. S. A. 106 2009 8754 8759
135. M. Regensburger, and et al. Adult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticity Neural Plast. 2014 2014 454696
136. O. Lamm, and et al. Harnessing neurogenesis for the possible treatment of Parkinson's disease J. Comp. Neurol. 522 2014 2817 2830
137. G.A. Carlesimo, and et al. Hippocampal abnormalities and memory deficits in Parkinson disease: a multimodal imaging study Neurology 78 2012 1939 1945
138. P. Luciani, and et al. Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model Cell. Mol. Life Sci. 67 2010 3711 3723
139. I. Salcedo, and et al. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders Br. J. Pharmacol. 166 2012 1586 1599
140. D.D. Belsham, and et al. Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons FASEB J. 23 2009 4256 4565
141. R. Isacson, and et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test Eur. J. Pharmacol. 650 2011 249 255
142. W.D. Porter, and et al. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice Int. J. Obes. (Lond.) 37 2013 678 684
143. H.H. Hansen, and et al. The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer's disease J. Alzheimers Dis. 46 2015 877 888
144. V.A. Gault, and C. Hölscher GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid Eur. J. Pharmacol. 587 2008 112 117
145. D.E. Read, and A.M. Gorman Involvement of Akt in neurite outgrowth Cell. Mol. Life Sci. 66 2009 2975 2984
146. M.H. Grider, and et al. Lipid raft-targeted Akt promotes axonal branching and growth cone expansion via mTOR and Rac1, respectively J. Neurosci. Res. 87 2009 3033 3042
147. V. Ries, and et al. Regulation of the postnatal development of dopamine neurons of the substantia nigra in vivo by Akt/protein kinase B J. Neurochem. 110 2009 23 33
148. M.I. Ransome, and A.J. Hannan Impaired basal and running-induced hippocampal neurogenesis coincides with reduced Akt signaling in adult R6/1 HD mice Mol. Cell. Neurosci. 54 2013 93 107
149. S. Casarosa, and et al. Mash1 regulates neurogenesis in the ventral telencephalon Development 126 1999 525 534
150. K. Oishi, and et al. Selective induction of neocortical GABAergic neurons by the PDK1-Akt pathway through activation of Mash1 Proc. Natl. Acad. Sci. U. S. A. 106 2009 13064 13069
151. G.M. Petzinger, and et al. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease Lancet Neurol. 12 2013 716 726
152. Z. Kohl, and et al. Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model Eur. J. Neurosci. 35 2012 10 19
153. P. Mohapel, and et al. Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions Neuroscience 132 2005 767 776
154. J.J. Ramos-Rodriguez, and et al. Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models PLOS ONE 9 2014 e89229
155. T. Ben-Hur, and et al. Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells Mol. Cell. Neurosci. 24 2003 623 631
156. K. Suzuki, and et al. Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine PLoS ONE 5 2010 e9260
157. S.B. Rangasamy, and et al. Neurotrophic factor therapy for Parkinson's disease Prog. Brain Res. 184 2010 237 264
158. M.J. Kelly, and et al. Viral vector delivery of neurotrophic factors for Parkinson's disease therapy Expert Rev. Mol. Med. 17 2015 e8
159. T.S. Bender, and et al. Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats Neuroscience 303 2015 569 576
160. A.H. Nagahara, and et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease Nat. Med. 15 2009 331 337
161. T. Perry, and et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells J. Pharmacol. Exp. Ther. 300 2002 958 966
162. T. Himeno, and et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice Diabetes 60 2011 2397 2406
163. M. Kan, and et al. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy J. Neuropathol. Exp. Neurol. 71 2012 494 510
164. T. Perry, and et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4 J. Pharmacol. Exp. Ther. 302 2002 881 888
165. Y. Li, and et al. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis PLoS ONE 7 2012 e32008
166. H. Zhou, and et al. Exendin-4 enhances the migration of adipose-derived stem cells to neonatal rat ventricular cardiomyocyte-derived conditioned medium via the phosphoinositide 3-kinase/Akt-stromal cell-derived factor-1α/CXC chemokine receptor 4 pathway Mol. Med. Rep. 11 2015 4063 4072
167. J. Liu, and et al. Exendin-4 pretreated adipose derived stem cells are resistant to oxidative stress and improve cardiac performance via enhanced adhesion in the infarcted heart PLOS ONE 9 2014 e99756
168. J. Liu, and et al. The stem cell adjuvant with Exendin-4 repairs the heart after myocardial infarction via STAT3 activation J. Cell. Mol. Med. 18 2014 1381 1391
169. J.L. Buss, and et al. Exenatide pretreatment improved graft function in nonhuman primate islet recipients compared to treatment after transplant only J. Transplant. 2012 2012 382518
170. M. Li, and et al. Liraglutide promotes cortical neurite outgrowth via the MEK-ERK pathway Cell. Mol. Neurobiol. 35 2015 987 993
171. H. Schroll, and et al. Dysfunctional and compensatory synaptic plasticity in Parkinson's disease Eur. J. Neurosci. 39 2014 688 702
172. B. Picconi, and et al. Synaptic dysfunction in Parkinson's disease Adv. Exp. Med. Biol. 970 2012 553 572
173. P. Calabresi, and et al. New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease Lancet Neurol. 12 2013 811 821
174. M.A. Hely, and et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years Mov. Disord. 23 2008 837 844
175. C.H. Williams-Gray, and et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort J. Neurol. Neurosurg. Psychiatry 84 2013 1258 1264
176. C.H. Williams-Gray, and et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort Brain 132 2009 2958 2969
177. C. Costa, and et al. Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease Brain 135 2012 1884 1899
178. T.P. Bouchard, and et al. Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease Neurobiol. Aging 29 2008 1027 1039
179. N. Ibarretxe-Bilbao, and et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia J. Neurol. 255 2008 1324 1331
180. P.L. Pan, and et al. Gray matter atrophy in Parkinson's disease with dementia: evidence from meta-analysis of voxel-based morphometry studies Neurol. Sci. 34 2013 613 619
181. I. Merchenthaler, and et al. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system J. Comp. Neurol. 403 1999 261 280
182. T. Abbas, and et al. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease Behav. Brain Res. 205 2009 265 271
183. M.J. During, and et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection Nat. Med. 9 2003 1173 1179
184. R. Hilker, and et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways Neurology 65 2005 1716 1722
185. E.K. Perry, and et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease J. Neurol. Neurosurg. Psychiatry 48 1985 413 421
186. J.M. Candy, and et al. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases J. Neurol. Sci. 59 1983 277 289
187. N.I. Bohnen, and et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study Arch. Neurol. 60 2003 1745 1748
188. N.I. Bohnen, and et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia J. Neurol. 253 2006 242 247
189. S.H. Choi, and et al. Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status Neurobiol. Aging 33 2012 1265 1272
190. D. Muslimovic, and et al. Cognitive profile of patients with newly diagnosed Parkinson disease Neurology 65 2005 1239 1245
191. J. Santiago, and J. Potashkin Shared dysregulated pathways lead to Parkinson's disease and diabetes Trends Mol. Med. 19 2013 176 186
192. J.K. Morris, and et al. Insulin resistance and gray matter volume in neurodegenerative disease Neuroscience 270 2014 139 147
193. M. Takahashi, and et al. Insulin receptor mRNA in the substantia nigra in Parkinson's disease Neurosci. Lett. 204 1996 201 204
194. A.I. Duarte, and et al. Insulin in central nervous system: more than just a peripheral hormone J. Aging Res. 2012 2012 384017
195. M. Tong, and et al. Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity J. Alzheimers Dis. 16 2009 585 599
196. E.C. Hirsch, and et al. Pathogenesis of Parkinson's disease Mov. Disord. 28 2013 24 30
197. L. Wang, and et al. Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice Exp. Neurol. 251 2014 22 29
198. J.K. Morris, and et al. Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet AJP Regul. Integr. Comp. Physiol. 299 2010 R1082 R1090
199. J.K. Morris, and et al. Insulin resistance impairs nigrostriatal dopamine function Exp. Neurol. 231 2011 171 180
200. J-Y. Choi, and et al. Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity Free Radic. Biol. Med. 38 2005 806 816
201. A. Kleinridders, and et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders Proc. Natl. Acad. Sci. U. S. A. 112 2015 3463 3468
202. J. Hirosumi, and et al. A central role for JNK in obesity and insulin resistance Nature 420 2002 333 336
203. F.R. Santos, and H.E. Diamond-Stanic Contribution of the serine kinase c-Jun N-terminal kinase (JNK) to oxidant-induced insulin resistance in isolated rat skeletal muscle Arch. Physiol. Biochem. 118 2012 231 236
204. F.G. De Felice, and et al. How does brain insulin resistance develop in Alzheimer's disease? Alzheimers Dement. 10 2014 S26 S32
205. S.T. Ferreira, and et al. Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease Alzheimers Dement. 10 2014 S76 S83
206. S. Gao, and et al. Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling Int. J. Biochem. Cell Biol. 64 2015 25 33
207. T.R. Bomfim, and et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers J. Clin. Invest. 122 2012 1339 1353
208. C.M. Long-Smith, and et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease Neuromol. Med. 15 2013 102 114
209. Y. Zhang, and et al. Geniposide attenuates insulin-deficiency-induced acceleration of β-amyloidosis in an APP/PS1 transgenic model of Alzheimer's disease Neurochem. Int. 89 2015 7 16
210. H. Hsuchou, and et al. Blood-borne metabolic factors in obesity exacerbate injury-induced gliosis J. Mol. Neurosci. 47 2012 267 277
211. M.M. Gonzales, and et al. Indirect effects of elevated body mass index on memory performance through altered cerebral metabolite concentrations Psychosom. Med. 74 2012 691 698
212. M.R. Hayes, and et al. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation Cell Metab. 13 2011 320 330
213. D.P. Bradley, and et al. Exenatide and weight loss Nutrition 26 2010 243 249
214. D. Beiroa, and et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK Diabetes 63 2014 3346 3358
215. L. Brunetti, and et al. Glucagon-like peptide 1 (7-36) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus Peptides 29 2008 1377 1381
216. J. Tong, and D.A. Sandoval Is the GLP-1 system a viable therapeutic target for weight reduction? Rev. Endocr. Metab. Disord. 12 2011 187 195
217. H.S. Sallam, and et al. Peripheral adipose tissue insulin resistance alters lipid composition and function of hippocampal synapses J. Neurochem. 133 2015 125 133
218. J. Yang, and et al. Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes Int. J. Mol. Med. 31 2013 1429 1435
219. T.D. Challa, and et al. Regulation of adipocyte formation by GLP-1/GLP-1R signaling J. Biol. Chem. 287 2012 6421 6430
220. S.K. Abbott, and et al. Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease Mov. Disord. 29 2014 518 526
221. M.M. Mielke, and et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study PLOS ONE 8 2013 e73094
222. B.T. Bikman A role for sphingolipids in the pathophysiology of obesity-induced inflammation Cell. Mol. Life Sci. 69 2012 2135 2146
223. L.E. Lyn-Cook, and et al. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis J. Alzheimers Dis. 16 2009 715 729
224. N. Tayebi, and et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol. Genet. Metab. 79 2003 104 109
225. O. Erbaş, and et al. Fatty liver-induced changes in stereotypic behavior in rats and effects of glucagon-like peptide-1 analog on stereotypy Kaohsiung J. Med. Sci. 30 2014 447 452
226. Q. Wang, and et al. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells Diabetologia 47 2004 478 487
227. H. Zhang, and et al. Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia Eur. J. Pharm. Sci. 70 2015 82 91
228. M-D. Wang, and et al. Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway Neuroscience 226 2012 388 396
229. L.A. Greene, and et al. Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment Cell. Mol. Neurobiol. 31 2011 969 978
230. S. Timmons, and et al. Akt signal transduction dysfunction in Parkinson's disease Neurosci. Lett. 467 2009 30 35
231. M. Elstner, and et al. Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death Acta Neuropathol. 122 2011 75 86
232. R.J. Griffin, and et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology J. Neurochem. 93 2005 105 117
233. S.R. Kim, and et al. Age and α-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling Neurobiol. Dis. 44 2011 215 222
234. C. Malagelada, and et al. RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation J. Neurosci. 28 2008 14363 14371
235. G. Xiromerisiou, and et al. Association between AKT1 gene and Parkinson's disease: a protective haplotype Neurosci. Lett. 436 2008 232 234
236. Y. Xu, and et al. Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease Cell. Signal. 26 2014 1680 1689
237. M. Canal, and et al. RTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disorders Front. Cell. Neurosci. 8 2014 313
238. M. Perrinjaquet, and et al. Protein-tyrosine phosphatase SHP2 contributes to GDNF neurotrophic activity through direct binding to phospho-Tyr687 in the RET receptor tyrosine kinase J. Biol. Chem. 285 2010 31867 31875
239. T. Yasuda, and H. Mochizuki Use of growth factors for the treatment of Parkinson's disease Expert Rev. Neurother. 10 2010 915 924
240. D.A. Foster, and A. Toschi Targeting mTOR with rapamycin: one dose does not fit all Cell Cycle 8 2009 1026 1029
241. C. O' Neill PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease Exp. Gerontol. 48 2013 647 653
242. D.E.A. Kloet, and B.M.T. Burgering The PKB/FOXO switch in aging and cancer Biochim. Biophys. Acta 1813 2011 1926 1937
243. M. Morissette, and et al. Striatal Akt/GSK3 signaling pathway in the development of l-Dopa-induced dyskinesias in MPTP monkeys Prog. Neuropsychopharmacol. Biol. Psychiatry 34 2010 446 454
244. S. Brunton GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int. J. Clin. Pract. 68 2014 557 567
245. J.B. Buse, and et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 381 2013 117 124
246. I. Aviles-Olmos, and et al. Exenatide and the treatment of patients with Parkinson's disease J. Clin. Invest. 123 2013 2730 2736
247. I. Aviles-Olmos, and et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease J. Parkinsons. Dis. 4 2014 337 344
248. M. Gejl, and et al. No decline of brain glucose metabolism in Alzheimer's disease patients treated with liraglutide American Diabetes Association, 75th Annual Meeting Boston, USA, June 5-9, 2015, abstr1309-P 2015
249. B. Finan, and et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents Nat. Med. 21 2015 27 36
250. B. Finan, and et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans Sci. Transl. Med. 5 2013 209ra151
251. C. Ji, and et al. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF Brain Res. 2015 S0006-8993
252. J. Janssens, and et al. Systems-level G protein-coupled receptor therapy across a neurodegenerative continuum by the GLP-1 receptor system Front. Endocrinol. (Lausanne) 5 2014 142
253. J. Seufert, and B. Gallwitz The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems Diabetes Obes. Metab. 16 2014 673 688
254. K.W. Sloop, and et al. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets Diabetes 59 2010 3099 3107
255. C. Koole, and et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening Mol. Pharmacol. 78 2010 456 465